The cost barrier in psilocybin therapy — who gets access?
78 replies · Therapy & Healing
Oregon psilocybin sessions run $1,500-3,500 depending on service center. Clinical trials provide free access but are geographically limited and highly selective. The people who arguably most need psilocybin-assisted therapy — those with severe, treatment-resistant conditions and limited resources — often have the least access. How do we think about this equity problem?
This is a real and serious equity issue. The current market structure in Oregon reflects the startup costs of a new industry with significant regulatory overhead, not the inherent cost of the intervention. Cost should come down as the market matures — but that's cold comfort for people who need access now.
The nonprofit sector is trying to bridge this: Heroic Hearts (for veterans), Zendo Project (crisis support), and some Oregon service centers offer sliding scale. But these are drops in the ocean relative to the population who could benefit. Systematic access will require insurance coverage, which requires FDA approval, which requires Phase 3 trial completion — we're 5-7 years from that best case.
Historical context worth keeping in mind: the same access inequality characterized the early phases of antiretroviral therapy, cognitive behavioral therapy, and every other effective but expensive medical intervention. Doesn't make it okay, but suggests the trajectory: access broadens as regulatory frameworks mature and manufacturing scales.
75 more replies — forum posting coming soon.